Postpartum Mh Htn denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for postpartum mh htn are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Imposes Quantity Limits on Postpartum Mental Health and Hypertension Medications

Quantity limits (QL) are restrictions Humana places on how much of a medication it will cover in a given time period — typically based on a standard dosing assumption from the FDA-approved label or from Humana's own clinical policy. In postpartum mental health and hypertension care, a prescriber may determine that the standard quantity is clinically insufficient for a particular patient's needs. When the prescribed quantity exceeds Humana's limit, a quantity-limit denial is issued.

## Why This Denial Is Appealable

Quantity limits are administrative defaults, not individualized clinical decisions. When your prescriber has documented a clinical rationale for a higher quantity — for example, that the condition severity requires it, or that the standard quantity leaves a coverage gap that creates clinical risk — Humana is required to consider a quantity-limit exception. Postpartum conditions can require individualized dosing decisions that differ from population-level defaults, and the treating clinician's documented judgment is the central piece of a successful appeal.

## Federal Appeal Framework

• Quantity-limit exception request: File this before or alongside a formal appeal. Humana must respond within defined timeframes.
• Internal appeal (ERISA §503 / state law): If the exception is denied, you may appeal internally. Submit within the timeframe on your denial notice.
• External review (ACA §2719): After final internal denial, independent external review is available within approximately four months.
• Expedited review: Request the expedited track if the standard-quantity gap creates urgent clinical risk — document the medical rationale for urgency explicitly.

## Documentation to Gather

1. Prescriber clinical justification letter: Explaining the medical reason the standard quantity is insufficient for your specific clinical situation, including the postpartum diagnosis, severity, and why the prescribed quantity is necessary. 2. FDA prescribing label: Reference the dosing section of the approved label. If the prescribed quantity falls within a labeled dosing range, make that explicit — Humana cannot override the label's own range. 3. Pharmacy dispensing history: Showing that you have used the standard quantity and it has been clinically insufficient, if applicable. 4. Diagnosis and severity records: Chart documentation supporting the postpartum mental health and/or hypertension diagnosis and current clinical status. 5. Humana's quantity-limit policy: Obtain the exact policy so your appeal addresses every stated criterion.

## Criteria-Mapping Structure

For each element of Humana's quantity-limit exception criteria, provide a direct answer from your chart:

| Humana QL Criterion | Your Evidence | |---|---| | Diagnosis requiring higher quantity | [Diagnosis, severity documentation, chart reference] | | Standard quantity is clinically insufficient | [Prescriber letter, dosing rationale, chart notes] | | Prescribed quantity within FDA label range | [FDA label section reference] | | Safety of requested quantity documented | [Prescriber attestation, monitoring plan if applicable] |

If the prescribed quantity is within the range listed in the FDA-approved prescribing label, highlight that fact prominently — it is often the most decisive argument against a quantity-limit denial.